IL17A and metabolic dysfunction-associated steatotic liver disease: Notably, although associated with NAFLD/NASH pathogenesis [22], IL-17A appears to mediate its effects through MAPK, NF-κB, and AP-1 which have all shown to be inhibited by curcumin [23].